Abstract PR006: Initial results of a cohort of advanced pancreatic cancer patients in a phase 1b Study of NGM120, a first-in-class anti-GDNF Family Receptor Alpha Like (GFRAL) antibody

MLA

Andrew Hendifar, et al. “Abstract PR006: Initial Results of a Cohort of Advanced Pancreatic Cancer Patients in a Phase 1b Study of NGM120, a First-in-Class Anti-GDNF Family Receptor Alpha Like (GFRAL) Antibody.” Cancer Research, vol. 82, Nov. 2022, p. PR006. EBSCOhost, https://doi.org/10.1158/1538-7445.panca22-pr006.

APA

Andrew Hendifar, Efrat Dotan, Benjamin Weinberg, Edward Kim, Peter Hosein, Jian Luo, Jiping Zha, Alex DePaoli, Vladimir Hanes, Cecilia Tranmuchowski, Kefei Zhou, Carol Tseng, & Hsiao Lieu. (2022). Abstract PR006: Initial results of a cohort of advanced pancreatic cancer patients in a phase 1b Study of NGM120, a first-in-class anti-GDNF Family Receptor Alpha Like (GFRAL) antibody. Cancer Research, 82, PR006. https://doi.org/10.1158/1538-7445.panca22-pr006

Chicago

Andrew Hendifar, Efrat Dotan, Benjamin Weinberg, Edward Kim, Peter Hosein, Jian Luo, Jiping Zha, et al. 2022. “Abstract PR006: Initial Results of a Cohort of Advanced Pancreatic Cancer Patients in a Phase 1b Study of NGM120, a First-in-Class Anti-GDNF Family Receptor Alpha Like (GFRAL) Antibody.” Cancer Research 82 (November): PR006. doi:10.1158/1538-7445.panca22-pr006.